Jason V. Coloma, Chief Executive Officer at Maze Therapeutics, Inc. (MAZE), sold 32,564 shares at $26.00 ($847K) on 2026-05-22, disclosed to the SEC on 2026-05-27.
Scheduled sale ($847k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.00 | 2,478 | $64K | 7.6% |
| 2 | $26.00 | 4,504 | $117K | 13.8% |
| 3 | $26.02 | 25,582 | $666K | 78.6% |
| Total | $26.01 avg | 32,564 | $847K | 100% |
| Filing → |
| MAZE | SELL | 2026-08-05 | $922K | — | Filing → |
| MAZE | SELL | 2026-07-02 | $1.0M | — | Filing → |
| MAZE | SELL | 2026-06-24 | $725K | — | Filing → |